Arbutus to Report Fourth Quarter and Year End 2020 Financial Results and Provide Corporate Update
February 22 2021 - 8:00AM
Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage
biopharmaceutical company primarily focused on developing a cure
for people with chronic hepatitis B virus (HBV) infection, as well
as therapies to treat coronaviruses (including COVID-19), today
announced that it has scheduled its fourth quarter and year end
2020 financial results and corporate update for Thursday, March 4,
2021. The schedule for the press release and conference
call/webcast are as follows:
• |
Q4 and Year End 2020 Press Release: |
March 4, 2021 at 7:30 a.m. ET |
• |
Q4 and Year End 2020 Conference Call/Webcast: |
March 4, 2021 at 8:45 a.m. ET |
• |
Domestic Dial-In Number: |
(866) 393-1607 |
• |
International Dial-In Number: |
(914) 495-8556 |
• |
Conference ID Number: |
4084504 |
A live webcast of the conference call can be
accessed through the Investors section of Arbutus' website at
www.arbutusbio.com or directly at Live Webcast.
An archived webcast will be available on the
Arbutus website after the event. Alternatively, you may access a
replay of the conference call by calling (855) 859-2056 or (404)
537-3406, and reference conference ID: 4084504.
About Arbutus
Arbutus Biopharma Corporation is a publicly
traded (Nasdaq: ABUS) biopharmaceutical company primarily dedicated
to discovering, developing and commercializing a cure for people
with chronic hepatitis B virus (HBV) infection. The Company is
advancing multiple drug product candidates that may be combined
into a potentially curative regimen for chronic HBV infection.
Arbutus has also initiated a drug discovery and development effort
for treating coronaviruses (including COVID-19). For more
information, visit www.arbutusbio.com.
Contact Information
Investors and Media
William H. CollierPresident and CEO Phone: 267-469-0914Email:
ir@arbutusbio.comPam MurphyInvestor Relations ConsultantPhone:
267-469-0914Email: ir@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Sep 2023 to Sep 2024